Allergy

Article	Citations
Risk factors for severe and critically ill COVID‐19 patients: A review	881
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19	787
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria	401
Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors	388
Type 2 immunity in the skin and lungs	298
EAACI guidelines: Anaphylaxis (2021 update)	201
The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens	191
Towards a more precise diagnosis of hypersensitivity to beta‐lactams — an EAACI position paper	174
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update	158
EAACI Biologicals Guidelines—Recommendations for severe asthma	158
Epithelial cell dysfunction, a major driver of asthma development	154
Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented?	146
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease	140
Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients	136
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice	130
Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma	129
Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status	126
Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)	125
The role of peripheral blood eosinophil counts in COVID‐19 patients	115
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation	112
Abstracts Poster	110
Is asthma protective against COVID‐19?	109
Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19	106
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?	101
Spotlight on microRNAs in allergy and asthma	101

The role of allergen‐specific IgE, IgG and IgA in allergic disease	98
Advances and recent developments in asthma in 2020	97
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement	95
Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic?	94
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches	93
Interleukin‐31: The “itchy” cytokine in inflammation and therapy	92
Advances and highlights in biomarkers of allergic diseases	91
Advances and highlights in allergic rhinitis	91
Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections	90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines	89
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2	85
Asthma and COVID‐19: Is asthma a risk factor for severe outcomes?	83
Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation	83
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biol	83
Is BCG vaccination affecting the spread and severity of COVID‐19?	80
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines	80
Advances and novel developments in allergic rhinitis	76
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19	76
A myoferlin gain‐of‐function variant associates with a new type of hereditary angioedema	74
The global burden of illness of peanut allergy: A comprehensive literature review	74
Regulatory B cells, A to Z	74
Butyrate as a bioactive human milk protective component against food allergy	73
The ingenious mast cell: Contemporary insights into mast cell behavior and function	73
Advances and highlights in asthma in 2021	73
EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma	72
Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement	71
Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy	71
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement	71
Predictors of treatment response in chronic spontaneous urticaria	69
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis	67
Frequency of food allergy in school‐aged children in eight European countries—The EuroPrevall‐iFAAM birth cohort	67
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations	67
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives	66
Biologics and airway remodeling in severe asthma	65
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation	65
Climate change and global health: A call to more research and more action	65
Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin	64
Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders	63
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper	63
Frequency of food allergy in Europe: An updated systematic review and meta‐analysis	62
In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion	62
Profound dysregulation of T cell homeostasis and function in patients with severe COVID‐19	61
Advances and novel developments in mechanisms of allergic inflammation	61
COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments	60
Abstracts	60
Elastase and exacerbation of neutrophil innate immunity are involved in multi‐visceral manifestations of COVID‐19	59
Allergen immunotherapy and/or biologicals for IgE‐mediated food allergy: A systematic review and meta‐analysis	58
Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity	58
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines	57
Global warming, climate change, air pollution and allergies	57

Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don't give up on the second dose!	56
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status	55
SARS‐CoV‐2, COVID‐19, skin and immunology – What do we know so far?	55
Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort	55
Cold urticaria – What we know and what we do not know	55
Risk factors for severe reactions in food allergy: Rapid evidence review with meta‐analysis	54
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – An EAACI‐ARIA Position Paper	54
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients	54
Adult‐onset eosinophilic airway diseases	53
Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper	52
Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID‐19	52
World Health Organization global air quality guideline recommendations: Executive summary	52
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma	52
Hypersensitivity reactions to chemotherapy: an EAACI Position Paper	51
The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria	50
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)	50
Expanding the allergen repertoire of salmon and catfish	48
Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19	48
The maternal diet index in pregnancy is associated with offspring allergic diseases: the Healthy Start study	47
Role of dietary fiber in promoting immune health—An EAACI position paper	47
IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria	47
COVID‐19 in a patient with severe asthma treated with Omalizumab	46
Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes	46
Mast cells and complement system: Ancient interactions between components of innate immunity	46
Accurate and reproducible diagnosis of peanut allergy using epitope mapping	45
Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps	45
Early intervention and prevention of allergic diseases	45
Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares	45
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled pha	45
Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA	44
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice	44
The diagnosis and management of allergic reactions in patients sensitized to non‐specific lipid transfer proteins	44
Basophils and their effector molecules in allergic disorders	44
Update on pathomechanisms and treatments in allergic rhinitis	44
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 201	43
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes	43
Skin tests in urticaria/angioedema and flushing to Pfizer‐BioNTech SARS‐CoV‐2 vaccine: Limits of intradermal testing	41
Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19	41
Skin pH–dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity	41
The neighbourhood natural environment is associated with asthma in children: A birth cohort study	40
Understanding the challenges faced by adolescents and young adults with allergic conditions: A systematic review	40
Breastfeeding promotes early neonatal regulatory T‐cell expansion and immune tolerance of non‐inherited maternal antigens	40
Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy	40
Ragweed plants grown under elevated CO2 levels produce pollen which elicit stronger allergic lung inflammation	40
Single‐cell molecular profiling provides a high‐resolution map of basophil and mast cell development	39
Eczema herpeticum in atopic dermatitis	38
Biologicals in atopic disease in pregnancy: An EAACI position paper	38
APPEAL‐1: A multiple‐country European survey assessing the psychosocial impact of peanut allergy	38
Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I	38
Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines	38
Basophil activation test shows high accuracy in the diagnosis of peanut and tree nut allergy: The Markers of Nut Allergy Study	38
Diagnosing, managing and preventing anaphylaxis: Systematic review	37
Mast cell activation is associated with post‐acute COVID‐19 syndrome	37
Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”	37
Immunological resilience and biodiversity for prevention of allergic diseases and asthma	37
Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID	37
Emollients in infancy to prevent atopic dermatitis: A systematic review and meta‐analysis	37
Asthma exacerbations on benralizumab are largely non‐eosinophilic	37
Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: A systematic review and meta‐analysis	36
Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study	36
Carbohydrate epitopes currently recognized as targets for IgE antibodies	36
Advances and novel developments in environmental influences on the development of atopic diseases	36
Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry	36
Estrogen receptor‐α signaling increases allergen‐induced IL‐33 release and airway inflammation	36
Allergens and their associated small molecule ligands—their dual role in sensitization	36
Skin‐infiltrating basophils promote atopic dermatitis‐like inflammation via IL‐4 production in mice	36
Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus	35
Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis	35
The role of CD23 in the regulation of allergic responses	35
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis	35
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence	35
Allergen‐specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways	34
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization	34
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis	34
Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma	34
Recent developments in the immunopathology of COVID‐19	34
Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study	33
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances	33
Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model	33
Eosinopenia is associated with greater severity in patients with coronavirus disease 2019	32

Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA	32
Early initiation of short‐term emollient use for the prevention of atopic dermatitis in high‐risk infants—The STOP‐AD randomised controlled trial	32
A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2	32
The effectiveness of interventions to improve self‐management for adolescents and young adults with allergic conditions: A systematic review	32
Antibodies in serum of convalescent patients following mild COVID‐19 do not always prevent virus‐receptor binding	32
Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi‐targeted approach	32
Infant gut microbiome is enriched with Bifidobacterium longumssp. infantis in Old Order Mennonites with traditional farming lifestyle	32
Glucagon‐like peptide‐1 receptor agonist inhibits aeroallergen‐induced activation of ILC2 and neutrophilic airway inflammation in obese mice	32
Biofilm propensity of Staphylococcus aureus skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort	32
Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease	31
Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper	31
Butyrate and propionate restore interleukin 13‐compromised esophageal epithelial barrier function	31
Quality of life of children aged 8‐12 years undergoing food allergy oral immunotherapy: Child and parent perspective	31
Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures	31
Molecular allergology and its impact in specific allergy diagnosis and therapy	31
Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions	31
Allergen immunotherapy for asthma prevention: A systematic review and meta‐analysis of randomized and non‐randomized controlled studies	30
Development and validation of combined symptom‐medication scores for allergic rhinitis*	30
Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria	30
Integration of metagenomics‐metabolomics reveals specific signatures and functions of airway microbiota in mite‐sensitized childhood asthma	30
Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: Results from the Italian Severe Asthma Registry	30
COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey	30
Accuracy of serological testing for SARS‐CoV‐2 antibodies: First results of a large mixed‐method evaluation study	29
Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study	29
Biology and dynamics of B cells in the context of IgE‐mediated food allergy	29
Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation: Implications in severe asthma	29
COVID‐19, chronic inflammatory respiratory diseases and eosinophils—Observations from reported clinical case series	29
Epithelial barrier dysfunction in ocular allergy	28
Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine	28
Prevalence and early‐life risk factors of school‐age allergic multimorbidity: The EuroPrevall‐iFAAM birth cohort	28
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases	28
Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper	28
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection	28
Impaired skin barrier and allergic sensitization in early infancy	28
Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment	28
Highlights in the advances of chronic rhinosinusitis	28
Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment	28
Mast cell‐derived serotonin enhances methacholine‐induced airway hyperresponsiveness in house dust mite‐induced experimental asthma	27
Circulating microRNA‐15b‐5p as a biomarker for asthma‐COPD overlap	27
Newly defined allergens in the WHO/IUIS Allergen Nomenclature Database during 01/2019‐03/2021	27
Interleukin‐6: A novel biomarker for monoclonal antibody and chemotherapy‐associated hypersensitivity confirms a cytokine release syndrome phenotype‐endotype association	27
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial	27
Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study	27
T‐cell subsets in the skin and their role in inflammatory skin disorders	27
Climate change: A call to action for the United Nations	27
Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses	27
Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines	27
Advanced forecasting of SARS‐CoV‐2‐related deaths in Italy, Germany, Spain, and New York State	27
Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis	27
Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry	27
Identification of Pru du 6 as a potential marker allergen for almond allergy	26
Cashew oral immunotherapy for desensitizing cashew‐pistachio allergy (NUT CRACKER study)	26
IL‐37 regulates allergic inflammation by counterbalancing pro‐inflammatory IL‐1 and IL‐33	26
Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry	26
Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis	26
Omics technologies in allergy and asthma research: An EAACI position paper	26
Association between ambient air pollution and development and persistence of atopic and non‐atopic eczema in a cohort of adults	25
Skin biomarkers predict development of atopic dermatitis in infancy	25
A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines	25
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study	25
Prevalence patterns of allergen sensitization by region, gender, age, and season among patients with allergic symptoms in mainland China: A four‐year multicenter study	25
The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions	25
Secretoglobins in the big picture of immunoregulation in airway diseases	25
SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age	25
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)	25
Translation and emerging functions of non‐coding RNAs in inflammation and immunity	25
Sputum macrophage diversity and activation in asthma: Role of severity and inflammatory phenotype	25
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus	25
Distinct expression of SARS‐CoV‐2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps	24
Effect of structural stability on endolysosomal degradation and T‐cell reactivity of major shrimp allergen tropomyosin	24
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies	24
iTRAQ‐based proteomic analysis reveals potential serum biomarkers of allergic and nonallergic asthma	24
Children of Asian ethnicity in Australia have higher risk of food allergy and early‐onset eczema than those in Singapore	24
Hypersensitivity reactions to biologicals: An EAACI position paper	24
Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report	24
In‐vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper	24
Single low‐dose exposure to cow’s milk at diagnosis accelerates cow’s milk allergic infants’ progress on a milk ladder programme	24
Association between asthma and clinical mortality/morbidity in COVID‐19 patients using clinical epidemiologic data from Korean Disease Control and Prevention	24
Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics	24
Global implementation of the world health organization's International Classification of Diseases (ICD)‐11: The allergic and hypersensitivity conditions model	24
Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response	24
β‐blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy	24
COVID‐19 vaccine anaphylaxis: IgE, complement or what else? A reply to: “COVID‐19 vaccine anaphylaxis: PEG or not?”	23
Abstract	23
Immune modulation via T regulatory cell enhancement: Disease‐modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task	23
Tolerance mechanisms of allergen immunotherapy	23
Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies	23
Predicting the recurrence of chronic rhinosinusitis with nasal polyps using nasal microbiota	23
Molecular sensitization patterns in animal allergy: Relationship with clinical relevance and pet ownership	23
Systemic allergic reactions induced by labile plant‐food allergens: Seeking potential cofactors. A multicenter study	23
EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis	23
Angiotensin‐converting enzyme II expression and its implication in the association between COVID‐19 and allergic rhinitis	23
Exiting the Anthropocene: Achieving personal and planetary health in the 21st century	23
The axis of the receptor for advanced glycation endproducts in asthma and allergic airway disease	23
The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine	23